New drug cocktail shows promise for Tough-to-Treat uterine cancer
NCT ID NCT02755844
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 26 times
Summary
This study tested a combination of three drugs (cyclophosphamide, metformin, and olaparib) in 35 women with advanced or metastatic endometrial cancer that had come back after standard chemotherapy. The goal was to find the safest dose and see if the combination could stop the cancer from growing. The approach aims to control the disease, not cure it, and patients may need ongoing treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Comité Gynécologique, Institut Gustave Roussy
Villejuif, 94800, France
-
Département d'Oncologie Médicale, Centre Antoine Lacassagne
Nice, 06189, France
-
Département de Cancérologie Cervico-Faciale et Thoracique, Centre Oscar Lambret
Lille, 59000, France
-
Service d'Oncologie Médicale, Centre François Baclesse
Caen, 14076, France
-
Service d'Oncologie Médicale, Institut Curie
Paris, 75248, France
Conditions
Explore the condition pages connected to this study.